Breast and Cervical Cancer Early Detection and Control Advisory Committee (BCCEDCAC), 61871-61872 [2014-24442]
Download as PDF
<![CDATA[
61871
Federal Register / Vol. 79, No. 199 / Wednesday, October 15, 2014 / Notices
concerning the proposed collection of
information are encouraged. Your
comments should address any of the
following: (a) Evaluate whether the
proposed collection of information is
necessary for the proper performance of
the functions of the agency, including
whether the information will have
practical utility; (b) Evaluate the
accuracy of the agencies estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected; (d) Minimize the burden of
the collection of information on those
who are to respond, including through
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and (e) Assess information
collection costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570 or
send an email to omb@cdc.gov. Written
comments and/or suggestions regarding
the items contained in this notice
should be directed to the Attention:
CDC Desk Officer, Office of Management
and Budget, Washington, DC 20503 or
by fax to (202) 395–5806. Written
comments should be received within 30
days of this notice.
Proposed Project
Annual Survey of the National Breast
and Cervical Cancer Early Detection
Program (NBCCEDP) Grantees—New—
National Center for Chronic Disease
Prevention and Health Promotion
(NCCDPHP), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
To improve access to cancer
screening, Congress passed the Breast
and Cervical Cancer Mortality
Prevention Act of 1990 (Pub. L. 101–
354) which directed CDC to create the
National Breast and Cervical Cancer
Early Detection Program (NBCCEDP).
Currently, the NBCCEDP funds 67
grantees including all 50 states, the
District of Columbia, 5 U.S. territories,
and 11 American Indian/Alaska Native
tribes or tribal organizations. Grantees
provide screening services for breast
and cervical cancer to low-income,
uninsured, and underinsured women
who otherwise would not have access to
screening.
The NBCCEDP is shifting from a focus
on direct service provision to
implementation of expanded evidencebased activities intended to increase
rates of breast and cervical cancer
screening at the population level.
Though NBCCEDP grantees continue to
provide breast and cervical cancer
screening for un- and underinsured
women, CDC is encouraging the
implementation of strategies to increase
screening rates beyond that of programeligible women. This data collection is
being proposed in order to assess
program implementation, particularly
related to these expanded populationbased efforts. A survey of NBCCEDP
grantees was originally fielded in Fall/
Winter 2013–2014 and cleared under
0920–0879 as ‘‘Assess Breast and
Cervical Cancer Screening Program
Activities to Expand Access to
Screening’’. The survey was found to be
useful by CDC and the awardees (which
received feedback reports). For example,
after the initial implementation of last
year’s survey, CDC was able to tailor
sessions at the Program Director’s
meeting to the needs of grantees that
had been expressed during last year’s
information collection. DCPC has
decided to continue the data collection
as an annual survey. Questions are of
various types including dichotomous
and multiple response.
This assessment will enable CDC to
gauge its progress in meeting NBCCEDP
program goals, identify implementation
activities, monitor program transition to
efforts aimed at impacting populationbased screening, identify technical
assistance needs of state, tribe and
territorial health department cancer
control programs, and identify
implementation models with potential
to expand and transition to new settings
to increase program impact and reach.
The assessment will identify successful
activities that should be maintained,
replicated, or expanded as well as
provide insight into areas that need
improvement.
OMB approval is requested for three
years. Participation is voluntary for
NBCCEDP awardees and there are no
costs to respondents other than their
time. The estimated burden per
response is 40 minutes and the total
estimated annualized burden hours are
45.
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondents
Breast and Cervical Cancer
Program Directors.
Number of
respondents
Form name
Annual Survey of the National Breast and Cervical Cancer
Early Detection Program (NBCCEDP) Grantees’ Program
Implementation.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2014–24438 Filed 10–14–14; 8:45 am]
tkelley on DSK3SPTVN1PROD with NOTICES
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
Breast and Cervical Cancer Early
Detection and Control Advisory
Committee (BCCEDCAC)
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),
VerDate Sep<11>2014
18:00 Oct 14, 2014
Jkt 235001
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
67
Number of
responses per
respondent
1
Average
burden per
response
(in hrs.)
40/60
announces the following meeting of the
aforementioned committee:
Times and Dates: 9:00 a.m.–5:00 p.m., EST,
November 6, 2014. 9:00 a.m.–12:30 p.m. EST,
November 7, 2014.
Place: CDC, 2900 Woodcock Boulevard,
University Office Park, Columbia Building,
Room 1064/1065, Atlanta, Georgia 30341.
Teleconference login information is as
follows:
For Participants:
TOLL-FREE PHONE #: 800–988–9707.
Participant passcode: 4798.
For Participants:
E:\FR\FM\15OCN1.SGM
15OCN1
61872
Federal Register / Vol. 79, No. 199 / Wednesday, October 15, 2014 / Notices
URL: https://www.mymeetings.com/nc/
join/.
Conference number: PW8992754.
Audience passcode: 4798.
Participants can join the event directly at:
https://www.mymeetings.com/nc/
join.php?i=PW8992754&p=4798&t=c.
There is also a toll number for anyone
outside of the USA:
TOLL PHONE #: 1 (312) 470–7387.
Participant passcode: 4798.
Status: Open to the public, limited only by
space and net conference and audio phone
lines available.
Purpose: The committee is charged with
advising the Secretary, Department of Health
and Human Services, and the Director, CDC,
regarding the early detection and control of
breast and cervical cancer. The committee
makes recommendations regarding national
program goals and objectives;
implementation strategies; and program
priorities including surveillance,
epidemiologic investigations, education and
training, information, dissemination,
professional interactions and collaborations,
and policy.
Matters for Discussion: The agenda will
include: (1) Discussing the impact of
implementation of the Affordable Care Act
on the National Breast and Cervical Cancer
Early Detection Program (NBCCEDP); (2)
assessing the needs of the public and impact
to the NBCCEDP; (3) population-based
activities to increase appropriate screening;
(4) screening communication tools; (5)
provider risk assessments.
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information:
Jameka R. Blackmon, MBA, CMP, Designated
Federal Officer, National Center for Chronic
Disease Prevention and Health Promotion,
CDC, 4770 Buford Highway NE., Mailstop
F76, Atlanta, Georgia 30341, Telephone (770)
488–4880.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Claudette Grant,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2014–24442 Filed 10–14–14; 8:45 am]
tkelley on DSK3SPTVN1PROD with NOTICES
BILLING CODE 4163–18–P
VerDate Sep<11>2014
18:00 Oct 14, 2014
Jkt 235001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2014–N–1491]
Agency Information Collection
Activities: Proposed Collection;
Comment Request; Survey of
Pharmacists and Patients; Variations
in the Physical Characteristics of
Generic Drug Pills and Patients’
Perceptions
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the Agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal Agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
the information collection associated
with a survey of pharmacists and
patients about their experiences
resulting from changes in generic drug
pill appearance.
DATES: Submit either electronic or
written comments on the collection of
information by December 15, 2014.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT: FDA
PRA Staff, Office of Operations, Food
and Drug Administration, 8455
Colesville Rd., COLE–14526, Silver
Spring, MD 20993–0002, PRAStaff@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
SUMMARY:
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Survey of Pharmacists and Patients:
Variations in the Physical
Characteristics of Generic Drug Pills
and Patients’ Perceptions—(OMB
Control Number 0910–NEW)
Generic drugs make up approximately
85 percent of all human prescription
drugs prescribed in the United States.
While generic drugs are required to be
pharmaceutically equivalent and
bioequivalent to their brand-name
counterparts, generics made by different
manufacturers may differ substantially
from their brand-name therapeutic
equivalents and from each other in their
physical appearance (e.g., color, shape,
or size of pills). When pharmacists
switch generic drug suppliers, patients
refilling their generic prescriptions may
therefore experience changes in their
drugs’ appearances. These changes may
result in patient confusion and concerns
about the safety and effectiveness of the
generic drug products. Studies indicate
that patients are more likely to stop
taking their generic medications when
they experience a change in their drugs’
physical appearances, leading to
harmful clinical and public health
consequences as well as increased
health care costs from avoidable
morbidity and mortality.
To provide additional information
that may help guide regulatory policy or
pharmacy business practices, we intend
to conduct surveys of pharmacists and
patients about their perceptions about
and experiences with generic drug
E:\FR\FM\15OCN1.SGM
15OCN1
]]>Agencies
[Federal Register Volume 79, Number 199 (Wednesday, October 15, 2014)]
[Notices]
[Pages 61871-61872]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-24442]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Breast and Cervical Cancer Early Detection and Control Advisory
Committee (BCCEDCAC)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC), announces the following meeting of the aforementioned
committee:
Times and Dates: 9:00 a.m.-5:00 p.m., EST, November 6, 2014.
9:00 a.m.-12:30 p.m. EST, November 7, 2014.
Place: CDC, 2900 Woodcock Boulevard, University Office Park,
Columbia Building, Room 1064/1065, Atlanta, Georgia 30341.
Teleconference login information is as follows:
For Participants:
TOLL-FREE PHONE #: 800-988-9707.
Participant passcode: 4798.
For Participants:
[[Page 61872]]
URL: https://www.mymeetings.com/nc/join/.
Conference number: PW8992754.
Audience passcode: 4798.
Participants can join the event directly at: https://www.mymeetings.com/nc/join.php?i=PW8992754&p=4798&t=c.
There is also a toll number for anyone outside of the USA:
TOLL PHONE #: 1 (312) 470-7387.
Participant passcode: 4798.
Status: Open to the public, limited only by space and net
conference and audio phone lines available.
Purpose: The committee is charged with advising the Secretary,
Department of Health and Human Services, and the Director, CDC,
regarding the early detection and control of breast and cervical
cancer. The committee makes recommendations regarding national
program goals and objectives; implementation strategies; and program
priorities including surveillance, epidemiologic investigations,
education and training, information, dissemination, professional
interactions and collaborations, and policy.
Matters for Discussion: The agenda will include: (1) Discussing
the impact of implementation of the Affordable Care Act on the
National Breast and Cervical Cancer Early Detection Program
(NBCCEDP); (2) assessing the needs of the public and impact to the
NBCCEDP; (3) population-based activities to increase appropriate
screening; (4) screening communication tools; (5) provider risk
assessments.
Agenda items are subject to change as priorities dictate.
Contact Person for More Information: Jameka R. Blackmon, MBA,
CMP, Designated Federal Officer, National Center for Chronic Disease
Prevention and Health Promotion, CDC, 4770 Buford Highway NE.,
Mailstop F76, Atlanta, Georgia 30341, Telephone (770) 488-4880.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities for both the Centers for Disease Control and Prevention
and the Agency for Toxic Substances and Disease Registry.
Claudette Grant,
Acting Director, Management Analysis and Services Office, Centers for
Disease Control and Prevention.
[FR Doc. 2014-24442 Filed 10-14-14; 8:45 am]
BILLING CODE 4163-18-P
